{"hands_on_practices": [{"introduction": "Effective management with magnesium sulfate begins with accurate administration. This fundamental practice exercise focuses on the critical skill of calculating infusion pump rates, ensuring that the prescribed therapeutic dose is delivered precisely. Mastering this calculation is a cornerstone of patient safety, preventing both underdosing and iatrogenic toxicity [@problem_id:4428617].", "problem": "A patient with severe preeclampsia requiring seizure prophylaxis is started on a maintenance infusion of Magnesium sulfate (MgSO$_4$) following a loading dose according to institutional protocol. The maintenance target is $2\\,\\mathrm{g/hour}$ delivered intravenously (IV). The hospital pharmacy provides a stock solution of MgSO$_4$ prepared as $40\\,\\mathrm{g}$ dissolved in $1000\\,\\mathrm{mL}$.\n\nUsing only fundamental definitions relating mass, volume, and rate, determine the infusion pump rate in $\\mathrm{mL/hour}$ required to deliver exactly $2\\,\\mathrm{g/hour}$ from this stock solution. Express your answer as a single real number in $\\mathrm{mL/hour}$.", "solution": "The problem as stated is a well-defined question in dimensional analysis and the application of fundamental definitions in a clinical context. It is scientifically grounded, objective, and contains all necessary information for a unique solution. Therefore, it is deemed valid.\n\nThe objective is to determine the volumetric infusion rate, $R_V$, in units of $\\mathrm{mL/hour}$, required to deliver a specific mass of a substance per unit time.\n\nLet us define the primary quantities involved:\n-   $C$: The concentration of the Magnesium sulfate (MgSO$_4$) stock solution. Concentration is defined as mass per unit volume.\n-   $R_M$: The target mass flow rate, which is the mass of MgSO$_4$ to be delivered per unit time.\n-   $R_V$: The volumetric flow rate, which is the volume of the solution to be delivered per unit time. This is the quantity we need to determine.\n\nThe fundamental relationship connecting these three quantities is that the mass flow rate is the product of the concentration and the volumetric flow rate. This can be derived from their definitions.\nIf $M$ is the mass and $V$ is the volume, then concentration $C = \\frac{M}{V}$.\nThis implies $M = C \\cdot V$.\nAssuming a constant concentration $C$, we can differentiate with respect to time $t$:\n$$\n\\frac{dM}{dt} = C \\cdot \\frac{dV}{dt}\n$$\nRecognizing that $R_M = \\frac{dM}{dt}$ and $R_V = \\frac{dV}{dt}$, we have:\n$$\nR_M = C \\cdot R_V\n$$\nTo find the required infusion pump rate $R_V$, we rearrange this equation:\n$$\nR_V = \\frac{R_M}{C}\n$$\nNow, we must determine the values of $R_M$ and $C$ from the problem statement.\n\nThe target mass flow rate is given as:\n$$\nR_M = 2\\,\\mathrm{g/hour}\n$$\nThe concentration $C$ of the stock solution must be calculated. The problem states that the solution is prepared by dissolving a mass $M_{stock} = 40\\,\\mathrm{g}$ of MgSO$_4$ in a total volume $V_{stock} = 1000\\,\\mathrm{mL}$.\nThe concentration $C$ is therefore:\n$$\nC = \\frac{M_{stock}}{V_{stock}} = \\frac{40\\,\\mathrm{g}}{1000\\,\\mathrm{mL}}\n$$\nCalculating this value, we find:\n$$\nC = 0.04\\,\\mathrm{g/mL}\n$$\nNow, we can substitute the values of $R_M$ and $C$ into our equation for $R_V$:\n$$\nR_V = \\frac{2\\,\\mathrm{g/hour}}{0.04\\,\\mathrm{g/mL}}\n$$\nWe perform the division. The units of grams ($\\mathrm{g}$) in the numerator and denominator cancel, leaving units of $\\mathrm{mL/hour}$, which is the desired unit for the infusion pump rate.\n$$\nR_V = \\frac{2}{0.04}\\,\\mathrm{mL/hour}\n$$\nTo simplify the fraction:\n$$\nR_V = \\frac{2}{\\frac{4}{100}}\\,\\mathrm{mL/hour} = \\frac{2 \\times 100}{4}\\,\\mathrm{mL/hour} = \\frac{200}{4}\\,\\mathrm{mL/hour}\n$$\n$$\nR_V = 50\\,\\mathrm{mL/hour}\n$$\nThus, the infusion pump must be set to a rate of $50\\,\\mathrm{mL/hour}$ to deliver the prescribed maintenance dose of $2\\,\\mathrm{g/hour}$ of Magnesium sulfate.", "answer": "$$\n\\boxed{50}\n$$", "id": "4428617"}, {"introduction": "Clinical practice often requires reconciling laboratory values reported in different units. This problem addresses the common task of converting serum magnesium concentrations between milliequivalents per liter ($ \\mathrm{mEq/L} $) and milligrams per deciliter ($ \\mathrm{mg/dL} $). More importantly, it challenges you to think beyond the numbers and consider the crucial limitations of relying solely on total serum magnesium levels for guiding therapy [@problem_id:4428527].", "problem": "A pregnant patient with severe preeclampsia is being treated with magnesium sulfate to prevent seizures. The therapeutic target for serum magnesium is reported in literature as a range of $4$–$7$ milliequivalents per liter, written as $4$–$7$ $\\mathrm{mEq/L}$, but the hospital laboratory reports magnesium as milligrams per deciliter, written as $\\mathrm{mg/dL}$. Starting from the fundamental definitions that (i) for a divalent cation such as magnesium, the absolute valence is $|z|=2$, (ii) the molar mass of elemental magnesium is $M_{\\mathrm{Mg}}=24.305$ $\\mathrm{g/mol}$, and (iii) $1$ $\\mathrm{dL}=0.1$ $\\mathrm{L}$, derive the general linear relationship between $\\mathrm{mEq/L}$ and $\\mathrm{mg/dL}$ for magnesium and apply it to convert the therapeutic range $4$–$7$ $\\mathrm{mEq/L}$ into $\\mathrm{mg/dL}$. Then, compute the arithmetic mean of the converted $\\mathrm{mg/dL}$ range as a single representative target value for this laboratory reporting convention. Round your final numerical answer to four significant figures. Express the final quantity in $\\mathrm{mg/dL}$.\n\nIn your reasoning, explain from first principles why such unit conversions work and articulate key limitations of relying on unit-converted total serum magnesium measurements alone for bedside dosing decisions in eclampsia.", "solution": "The task is to convert a concentration reported in $\\mathrm{mEq/L}$ to $\\mathrm{mg/dL}$ for magnesium and then compute a single representative value (the arithmetic mean) of the converted range. We begin with fundamental definitions connecting equivalents, moles, and mass.\n\nFor an ion of absolute valence $|z|$, the relationship between milliequivalents per liter and millimoles per liter is\n$$\n\\text{mEq/L} = |z| \\times \\text{mmol/L}.\n$$\nEquivalently,\n$$\n\\text{mmol/L} = \\frac{\\text{mEq/L}}{|z|}.\n$$\nTo convert millimoles to milligrams, we use the molar mass. For magnesium, the molar mass is $M_{\\mathrm{Mg}}=24.305$ $\\mathrm{g/mol}$, which is $24{,}305$ $\\mathrm{mg/mol}$ or $24.305$ $\\mathrm{mg/mmol}$. The relationship between $\\mathrm{mg/dL}$ and $\\mathrm{mmol/L}$ is\n$$\n\\text{mg/dL} = \\left(\\text{mmol/L}\\right)\\times \\left(\\frac{M_{\\mathrm{Mg}} \\ \\text{mg}}{\\text{mmol}}\\right)\\times \\left(\\frac{1 \\ \\text{L}}{10 \\ \\text{dL}}\\right).\n$$\nSubstituting $\\text{mmol/L}=\\frac{\\text{mEq/L}}{|z|}$ gives the general linear conversion for magnesium:\n$$\n\\text{mg/dL} = \\left(\\frac{\\text{mEq/L}}{|z|}\\right)\\times M_{\\mathrm{Mg}} \\times \\frac{1}{10}\n= \\frac{M_{\\mathrm{Mg}}}{10|z|}\\times \\text{mEq/L}.\n$$\nFor magnesium, $|z|=2$ and $M_{\\mathrm{Mg}}=24.305$ $\\mathrm{g/mol}$, so the conversion factor $F$ from $\\mathrm{mEq/L}$ to $\\mathrm{mg/dL}$ is\n$$\nF=\\frac{M_{\\mathrm{Mg}}}{10|z|}=\\frac{24.305}{20}=1.21525.\n$$\nTherefore,\n$$\n\\text{mg/dL} = 1.21525 \\times \\text{mEq/L}.\n$$\nThis fundamental derivation is numerically equivalent to the empirical relation $\\text{mg/dL} \\approx \\frac{\\text{mEq/L}}{0.823}$, because\n$$\n\\frac{10|z|}{M_{\\mathrm{Mg}}}=\\frac{20}{24.305}\\approx 0.8230,\n$$\nso dividing by $0.823$ is the same as multiplying by $1.21525$ to the precision shown.\n\nNext, convert the therapeutic range $4$–$7$ $\\mathrm{mEq/L}$:\n- Lower bound in $\\mathrm{mg/dL}$:\n$$\n4 \\ \\mathrm{mEq/L} \\ \\longrightarrow \\ 4 \\times 1.21525 = 4.861 \\ \\mathrm{mg/dL}.\n$$\n- Upper bound in $\\mathrm{mg/dL}$:\n$$\n7 \\ \\mathrm{mEq/L} \\ \\longrightarrow \\ 7 \\times 1.21525 = 8.50675 \\ \\mathrm{mg/dL}.\n$$\nThe arithmetic mean of the converted range is\n$$\n\\frac{4.861 + 8.50675}{2} = \\frac{13.36775}{2} = 6.683875 \\ \\mathrm{mg/dL}.\n$$\nRounding to four significant figures yields $6.684$ $\\mathrm{mg/dL}$.\n\nLimitations of such conversions in clinical practice:\n- The conversion assumes that total serum magnesium concentration maps directly to pharmacodynamic effect, but the anticonvulsant effect relates to biologically active free (ionized) magnesium. Total and ionized magnesium can diverge in conditions affecting protein binding, acid–base balance, and sample handling, even though magnesium binding is relatively modest compared to calcium.\n- Assay variability and matrix differences (serum versus plasma), preanalytical issues (e.g., hemolysis releasing intracellular magnesium), and calibration differences can affect reported values independently of unit conversion.\n- Timing relative to dosing matters. After an intravenous loading dose, serum magnesium may transiently exceed steady-state therapeutic levels before redistribution; a single measurement may not reflect tissue levels or central nervous system effect at that moment.\n- Patient factors such as renal function, fluid shifts in pregnancy and the postpartum period, and concomitant medications influence magnesium kinetics and toxicity risk; thus, the same serum value may have different clinical implications across patients.\n- Bedside management of eclampsia prioritizes clinical endpoints—such as preservation of deep tendon reflexes, adequate respiratory rate, and sufficient urine output—over exact numerical targets, using levels as adjuncts rather than sole determinants of dosing.\n\nThus, while the unit conversion is valid and useful for interfacing with laboratory reporting conventions, therapeutic decisions should integrate clinical assessment and context, recognizing the limitations of total serum magnesium measurements.\n\nThe requested single representative value (the arithmetic mean of the converted range), rounded to four significant figures, is $6.684$ $\\mathrm{mg/dL}$.", "answer": "$$\\boxed{6.684}$$", "id": "4428527"}, {"introduction": "This practice presents a high-fidelity clinical scenario that synthesizes the principles of magnesium sulfate management under challenging conditions. You are tasked with managing a patient developing acute kidney injury and early signs of toxicity, requiring you to integrate laboratory data, physical exam findings, and pharmacokinetic principles. Your decision will test your ability to act decisively to prevent severe adverse outcomes while maintaining necessary seizure prophylaxis [@problem_id:4428668].", "problem": "A $28$-year-old gravida $1$ para $0$ at $35$ weeks' gestation is admitted with severe preeclampsia and started on magnesium sulfate for seizure prophylaxis with a loading dose of $6\\,\\text{g}$ intravenously over $20$ minutes followed by a maintenance infusion of $2\\,\\text{g/h}$. Over the first $3$ hours, her urine output has progressively decreased to $20\\,\\text{mL/h}$, and her serum creatinine has risen from $0.9\\,\\text{mg/dL}$ to $1.6\\,\\text{mg/dL}$. Her blood pressure remains $165/105\\,\\text{mmHg}$ on antihypertensives. Deep tendon reflexes (DTRs) are present but diminished, and her respiratory rate (RR) is $14$ breaths per minute. She has no clonus and no respiratory distress. Fetal status is reassuring.\n\nMagnesium sulfate is primarily eliminated by renal excretion and, under continuous infusion, its steady-state concentration depends on the relationship between infusion rate and clearance. In the setting of impaired renal function, there is a risk of hypermagnesemia with clinical toxicity, including loss of deep tendon reflexes, respiratory depression, and cardiac conduction abnormalities. Standard clinical monitoring during magnesium sulfate infusion includes serial assessments of deep tendon reflexes, respiratory rate, and urine output. Serum magnesium levels are typically measured when renal function is impaired or when toxicity is suspected. Calcium gluconate is the antidote for magnesium toxicity.\n\nWhich of the following bundled orders and monitoring changes is the most appropriate next step to justify and implement now, given the rising serum creatinine and decreasing urine output after initiation of magnesium sulfate?\n\nA. Continue the magnesium sulfate infusion at $2\\,\\text{g/h}$; defer serum magnesium measurement until $24$ hours; check deep tendon reflexes every $4$ hours; no change in respiratory rate or urine output monitoring.\n\nB. Immediately pause the magnesium sulfate infusion and obtain a stat serum magnesium level; assess deep tendon reflexes, respiratory rate, and urine output hourly; if the serum magnesium level is within the therapeutic range and there are no signs of toxicity, resume magnesium sulfate at $1\\,\\text{g/h}$; repeat serum magnesium every $4$–$6$ hours while oliguria persists; repeat a basic metabolic panel (BMP) including serum creatinine every $12$ hours; be prepared to administer $10\\,\\text{mL}$ of $10\\%$ calcium gluconate intravenously if toxicity develops.\n\nC. Discontinue magnesium sulfate permanently due to rising creatinine and start phenytoin; no further magnesium measurements are needed; monitor deep tendon reflexes every $8$ hours.\n\nD. Maintain magnesium sulfate at $2\\,\\text{g/h}$ and increase intravenous fluids to $200\\,\\text{mL/h}$ to restore urine output; obtain a serum magnesium level only if deep tendon reflexes are absent or respiratory rate is less than $12$ breaths per minute; check vital signs every $8$ hours.\n\nE. Reduce magnesium sulfate to $1.5\\,\\text{g/h}$; obtain a serum magnesium level once daily; check deep tendon reflexes every $2$ hours; increase the dose back to $2\\,\\text{g/h}$ if the level is below the therapeutic range.", "solution": "## Problem Validation\n\n### Step 1: Extract Givens\nThe problem statement provides the following information:\n*   **Patient Profile:** A $28$-year-old female patient, gravida $1$, para $0$.\n*   **Gestational Age:** $35$ weeks.\n*   **Diagnosis:** Severe preeclampsia.\n*   **Intervention:** Initiation of magnesium sulfate ($MgSO_4$) for seizure prophylaxis.\n*   **Dosage Regimen:**\n    *   Loading dose: $6$ g intravenously (IV) over $20$ minutes.\n    *   Maintenance infusion: $2$ g per hour.\n*   **Clinical Findings over the first $3$ hours:**\n    *   Urine output: Decreased to $20$ mL per hour.\n    *   Serum creatinine: Increased from $0.9$ mg/dL to $1.6$ mg/dL.\n    *   Blood pressure: $165/105$ mmHg, while on antihypertensive medication.\n    *   Deep tendon reflexes (DTRs): Present but diminished.\n    *   Respiratory rate (RR): $14$ breaths per minute.\n    *   Clonus: Absent.\n    *   Respiratory distress: Absent.\n*   **Fetal Status:** Reassuring.\n*   **Pharmacokinetic/Pharmacodynamic Principles Stated:**\n    *   $MgSO_4$ is primarily eliminated by renal excretion.\n    *   In renal impairment, there is a risk of hypermagnesemia and clinical toxicity (loss of DTRs, respiratory depression, cardiac abnormalities).\n    *   Standard monitoring includes DTRs, RR, and urine output.\n    *   Serum magnesium levels are indicated for impaired renal function or suspected toxicity.\n    *   Calcium gluconate is the antidote for $MgSO_4$ toxicity.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is evaluated against the established criteria:\n\n*   **Scientifically Grounded:** The scenario is entirely consistent with established medical principles in obstetrics and pharmacology. The pathophysiology of severe preeclampsia, its potential to cause acute kidney injury (AKI), the pharmacokinetics of magnesium sulfate (renal clearance), and the signs and symptoms of magnesium toxicity are all factually and scientifically sound. The provided clinical values are realistic for such a presentation.\n*   **Well-Posed:** The problem presents a clear, specific clinical situation with sufficient data to allow for a reasoned decision on the next steps in management. It asks for the \"most appropriate\" action, which implies a single best choice based on standard-of-care guidelines.\n*   **Objective:** The problem is described using objective clinical data (e.g., urine output in mL/hr, serum creatinine in mg/dL, RR in breaths/minute) and standard clinical observations (diminished DTRs). The language is precise and free of bias or subjective claims.\n\nThe problem does not exhibit any of the flaws listed in the validation instructions. The data are internally consistent: the oliguria ($20$ mL/hr is less than the typical threshold of $30$ mL/hr) and the significant rise in serum creatinine (an increase of $>0.3$ mg/dL and $>1.5$ times baseline) clearly indicate AKI. This developing AKI explains the early sign of magnesium toxicity (diminished DTRs), as the clearance of the infused magnesium is impaired.\n\n### Step 3: Verdict and Action\nThe problem statement is valid. The solution process will proceed.\n\n## Derivation of a Solution\n\nThe core of the problem lies in the interplay between the patient's severe preeclampsia, the development of acute kidney injury (AKI), and the administration of magnesium sulfate, a drug cleared by the kidneys.\n\n1.  **Identify the Critical Clinical Change:** The patient is developing AKI. This is unequivocally demonstrated by the decrease in urine output to oliguric levels ($20$ mL/hour) and the acute, significant rise in serum creatinine from a baseline of $0.9$ mg/dL to $1.6$ mg/dL in just $3$ hours.\n\n2.  **Analyze the Pharmacokinetic Implications:** Magnesium sulfate is eliminated almost exclusively via renal excretion. The rate of drug elimination (clearance, $Cl$) is therefore proportional to renal function. With a continuous infusion at a rate ($R_0$) of $2$ g/hour, the steady-state plasma concentration ($C_{ss}$) is given by the relationship $C_{ss} = R_0 / Cl$. As the patient's renal function declines, her magnesium clearance ($Cl$) decreases. Consequently, with a constant infusion rate $R_0$, the serum magnesium concentration will rise progressively.\n\n3.  **Evaluate for Magnesium Toxicity:** The therapeutic range for seizure prophylaxis is typically $4.8$ to $8.4$ mg/dL (or $4$ to $7$ mEq/L). The patient is exhibiting diminished DTRs, which is the first classic sign of magnesium toxicity. This sign usually appears when serum levels reach $7-10$ mEq/L ($8.5 - 12$ mg/dL). While her respiratory rate is still normal (RR = $14$; respiratory depression typically occurs at levels $>12$ mg/dL or with an RR $< 12$ breaths/minute), the diminished DTRs are a crucial warning sign that the patient is accumulating magnesium to a supratherapeutic, and potentially dangerous, level.\n\n4.  **Formulate an Appropriate Management Plan:** Based on the above analysis, the immediate priorities are to prevent life-threatening toxicity (respiratory arrest, cardiac arrest) while ensuring continued, adequate seizure prophylaxis. This requires the following steps:\n    *   **Halt Magnesium Accumulation:** The most immediate action must be to stop the source of the magnesium. The infusion must be paused or stopped. Continuing the infusion, even at a reduced rate, is unsafe without first knowing the current serum level.\n    *   **Quantify the Toxicity:** A stat (immediate) serum magnesium level is essential to determine the degree of hypermagnesemia. This result will guide all subsequent decisions regarding restarting the infusion and at what dose.\n    *   **Intensify Monitoring:** Given the clear evidence of AKI and an early sign of toxicity, clinical monitoring must be increased in frequency. Hourly checks of DTRs, respiratory rate, and continuous urine output assessment are warranted to detect any worsening toxicity promptly.\n    *   **Re-evaluate and Adjust Therapy:** Seizure prophylaxis remains critical. Once the magnesium level is known and if the patient is clinically stable (no further signs of progressive toxicity), the infusion can be considered for restart, but at a significantly reduced rate (e.g., half the standard rate, $1$ g/hour) appropriate for impaired renal function.\n    *   **Monitor Renal Function:** The underlying AKI must be monitored closely with serial measurements of serum creatinine (e.g., via a basic metabolic panel).\n    *   **Prepare for Emergency:** The antidote for severe magnesium toxicity, calcium gluconate, must be readily available at the bedside for immediate administration if signs of severe toxicity (e.g., respiratory depression, absent DTRs, hypotension) develop.\n\n## Option-by-Option Analysis\n\n**A. Continue the magnesium sulfate infusion at $2$ g per hour; defer serum magnesium measurement until $24$ hours; check deep tendon reflexes every $4$ hours; no change in respiratory rate or urine output monitoring.**\nThis plan is grossly negligent. Continuing the infusion at $2$ g/hr in the setting of documented AKI and emerging toxicity (diminished DTRs) would predictably lead to severe, life-threatening hypermagnesemia. Deferring the serum magnesium level and reducing the frequency of monitoring is the opposite of the required action.\n**Verdict: Incorrect**\n\n**B. Immediately pause the magnesium sulfate infusion and obtain a stat serum magnesium level; assess deep tendon reflexes, respiratory rate, and urine output hourly; if the serum magnesium level is within the therapeutic range and there are no signs of toxicity, resume magnesium sulfate at $1$ g per hour; repeat serum magnesium every $4$–$6$ hours while oliguria persists; repeat a basic metabolic panel (BMP) including serum creatinine every $12$ hours; be prepared to administer $10$ mL of $10\\%$ calcium gluconate intravenously if toxicity develops.**\nThis option aligns perfectly with the derived management plan. It correctly prioritizes patient safety by pausing the infusion. It calls for the essential diagnostic test (stat magnesium level) and intensifies monitoring (hourly checks). It provides a sound, conditional plan for resuming seizure prophylaxis at a reduced, safer dose ($1$ g/hr), guided by lab results. It includes ongoing monitoring of both magnesium levels and renal function. Finally, it incorporates the critical safety measure of having the antidote ready. This is a comprehensive and correct approach.\n**Verdict: Correct**\n\n**C. Discontinue magnesium sulfate permanently due to rising creatinine and start phenytoin; no further magnesium measurements are needed; monitor deep tendon reflexes every $8$ hours.**\nThis is an incorrect and suboptimal plan. Magnesium sulfate is the first-line, superior agent for eclampsia prophylaxis. Phenytoin is a less effective, second-line agent. Switching agents unnecessarily exposes the patient to a higher risk of seizures. Discontinuing $MgSO_4$ permanently may not be necessary if it can be safely managed at a lower dose. Failing to measure the current magnesium level ignores the immediate risk of toxicity from the drug already administered. Reducing monitoring frequency is inappropriate.\n**Verdict: Incorrect**\n\n**D. Maintain magnesium sulfate at $2$ g per hour and increase intravenous fluids to $200$ mL per hour to restore urine output; obtain a serum magnesium level only if deep tendon reflexes are absent or respiratory rate is less than $12$ breaths per minute; check vital signs every $8$ hours.**\nSimilar to option A, maintaining the infusion at $2$ g/hr is dangerous. Aggressive fluid resuscitation ($200$ mL/hr) can be hazardous in patients with severe preeclampsia, who have endothelial dysfunction and are at high risk for pulmonary edema. Most critically, delaying a serum magnesium measurement until DTRs are *absent* or respiratory depression is present means waiting for signs of severe, potentially fatal toxicity. This is an unacceptable delay. The reduced monitoring frequency is also unsafe.\n**Verdict: Incorrect**\n\n**E. Reduce magnesium sulfate to $1.5$ g per hour; obtain a serum magnesium level once daily; check deep tendon reflexes every $2$ hours; increase the dose back to $2$ g per hour if the level is below the therapeutic range.**\nWhile reducing the dose to $1.5$ g/hr is a step in the right direction, it is not the safest initial action. The infusion should be paused entirely until the current magnesium level is known, as even $1.5$ g/hr could be excessive. Measuring the level only once daily is too infrequent for this acute and rapidly changing clinical scenario. This plan is less safe and proactive compared to option B.\n**Verdict: Incorrect**", "answer": "$$\\boxed{B}$$", "id": "4428668"}]}